The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system
This study, based on real-world data, revealed significant signals indicating that ACEI use during the COVID-19 pandemic may have increased the risk of renal adverse events and ear labyrinth diseases. The study emphasized the need for increased caution when using ACEIs and ARBs during the pandemic.
Authors
- Xin Huang (ORCID: https://orcid.org/0000-0002-3395-0964)
- Zeying Feng (ORCID: https://orcid.org/0000-0002-7283-9564)
- Chengxian Guo (ORCID: https://orcid.org/0000-0002-6332-6716)
- Jiankui Zhou (ORCID: https://orcid.org/0000-0002-7099-4528)
- Hui Qiu (ORCID: https://orcid.org/0000-0002-5819-0965)
- Tong Li (ORCID: https://orcid.org/0000-0002-9243-0379)
- Ling Ye (ORCID: https://orcid.org/0000-0002-2744-0255)
- Chengjun Guo (ORCID: https://orcid.org/0000-0002-8843-3032)
- Li He
- Shaojun Chen (ORCID: https://orcid.org/0009-0006-3369-4426)
- Longjian Huang
Institutions
- Guangdong University of Technology (CN)
- Central South University (CN)
- National Clinical Research (US)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Fourth Affiliated Hospital of Guangxi Medical University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1080/14740338.2025.2465865
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Natural Science Foundation of Hunan Province